Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Macrophages sense and kill bacteria through carbon monoxide–dependent inflammasome activation
Barbara Wegiel, Rasmus Larsen, David Gallo, Beek Yoke Chin, Clair Harris, Praveen Mannam, Elzbieta Kaczmarek, Patty J. Lee, Brian S. Zuckerbraun, Richard Flavell, Miguel P. Soares, Leo E. Otterbein
Barbara Wegiel, Rasmus Larsen, David Gallo, Beek Yoke Chin, Clair Harris, Praveen Mannam, Elzbieta Kaczmarek, Patty J. Lee, Brian S. Zuckerbraun, Richard Flavell, Miguel P. Soares, Leo E. Otterbein
View: Text | PDF
Research Article Immunology

Macrophages sense and kill bacteria through carbon monoxide–dependent inflammasome activation

  • Text
  • PDF
Abstract

Microbial clearance by eukaryotes relies on complex and coordinated processes that remain poorly understood. The gasotransmitter carbon monoxide (CO) is generated by the stress-responsive enzyme heme oxygenase-1 (HO-1, encoded by Hmox1), which is highly induced in macrophages in response to bacterial infection. HO-1 deficiency results in inadequate pathogen clearance, exaggerated tissue damage, and increased mortality. Here, we determined that macrophage-generated CO promotes ATP production and release by bacteria, which then activates the Nacht, LRR, and PYD domains-containing protein 3 (NALP3) inflammasome, intensifying bacterial killing. Bacterial killing defects in HO-1–deficient murine macrophages were restored by administration of CO. Moreover, increased CO levels enhanced the bacterial clearance capacity of human macrophages and WT murine macrophages. CO-dependent bacterial clearance required the NALP3 inflammasome, as CO did not increase bacterial killing in macrophages isolated from NALP3-deficient or caspase-1–deficient mice. IL-1β cleavage and secretion were impaired in HO-1–deficient macrophages, and CO-dependent processing of IL-1β required the presence of bacteria-derived ATP. We found that bacteria remained viable to generate and release ATP in response to CO. The ATP then bound to macrophage nucleotide P2 receptors, resulting in activation of the NALP3/IL-1β inflammasome to amplify bacterial phagocytosis by macrophages. Taken together, our results indicate that macrophage-derived CO permits efficient and coordinated regulation of the host innate response to invading microbes.

Authors

Barbara Wegiel, Rasmus Larsen, David Gallo, Beek Yoke Chin, Clair Harris, Praveen Mannam, Elzbieta Kaczmarek, Patty J. Lee, Brian S. Zuckerbraun, Richard Flavell, Miguel P. Soares, Leo E. Otterbein

×

Figure 5

Effects of CO on bacteria-derived ATP generation and macrophage-killing response.

Options: View larger image (or click on image) Download as PowerPoint
Effects of CO on bacteria-derived ATP generation and macrophage-killing ...
(A) ATP generation by E. faecalis (106) ± CO for 1 hour measured colorimetrically (inset) or fluorometrically. (B) ATP fluorescence in supernatants from E. coli (104) treated for 6 hours ± CO. *P < 0.05; **P < 0.001. (C and D) Interaction between E. coli–derived 32ATP and immunoprecipitated BMDM P2X7 receptor from WT and P2rx7–/– mice (D) treated with supernatant from CO-exposed 32ATP-producing bacteria. Neg, IgG control; A, ampicillin control. *P < 0.03; #P < 0.05, CO versus air. (E) 32ATP-producing bacteria supernatant exposed to BMDMs where HO-1 was induced by LPS to increase endogenous CO by HO-1 ± QC-15 to block HO-1. *P < 0.01, LPS versus control (C); #P < 0.05, LPS versus LPS + QC. (F) Bacterial counts in BMDM supernatants infected with E. faecalis for 1 hour, then ± ATP (50 μM) for an additional 6 hours. *P < 0.05. (G) ATP in supernatants of WT E. coli MG1665 or ΔatpA E. coli (104) treated 30 minutes with CO or air expressed as fold change to account for proliferation rate differences. Data represent mean ± SD of 3 experiments in triplicate. *P < 0.02, CO + M1655 versus air + M1655. (H) Immunoblot with antibodies against IL-1β lysates of WT or mutant E. coli–treated BMDMs ± CO as above. (I) Bacterial counts expressed as fold change due to differences in proliferative rates. BMDMs were infected for 1 hour, then treated ± CO for an additional 6 hours. **P < 0.01, CO versus WT E. coli (102). *P < 0.05, CO + ΔcyoB versus air + ΔcyoB; &P < 0.04, CO + Δcyd versus air + Δcyd. (J) WT or mutant E. coli growth ± CO. Results represent mean ± SD from 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts